What does this research mean for the field?

One year of vosoritide treatment significantly increases linear growth in children with hypochondroplasia and has a favorable safety profile. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.ESTABLISHES_NEW_DIRECTION.

What question did this study set out to answer?

To evaluate the efficacy and safety of daily vosoritide treatment compared with placebo in children with hypochondroplasia.

September 10, 2026NEJM Evidence

A Phase 3 Trial of Vosoritide in Children with Hypochondroplasia

View Full Paper

Ask AI

Bookmark

To evaluate the efficacy and safety of daily vosoritide treatment compared with placebo in children with hypochondroplasia.
In a phase 3 multicenter trial, 81 children aged 3 to <18 years were randomly assigned to receive once-daily subcutaneous injections of vosoritide (n=41) or placebo (n=40) for 52 weeks (NCT06455059).
The primary end point was the change from baseline in annualized growth velocity at week 52 versus placebo, assessed with hierarchical confirmatory testing.
At week 52, least squares mean change in annualized growth velocity was 1.95 cm/year with vosoritide versus -0.39 cm/year with placebo (difference: 2.33 cm/year; 95% CI, 1.85-2.82; two-sided P<0.0001).
Adverse events occurred in 87.8% of vosoritide recipients and 72.5% of placebo recipients, with no grade 3 or higher events, treatment discontinuations, or deaths.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Randomized trial demonstrates increased annualized growth velocity with vosoritide in children with hypochondroplasia, highlighting its potential as a targeted therapy.

Cite This Study

Dauber et al. (2026) studied this question.

synapsesocial.com/papers/6aa27c2058559d80afc75b79 https://doi.org/10.1056/evidoa2600257

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial demonstrates increased annualized growth velocity with vosoritide in children with hypochondroplasia, highlighting its potential as a targeted therapy.

A Phase 3 Trial of Vosoritide in Children with Hypochondroplasia

Key Points

Discussion

Implication

Cite This Study

A Phase 3 Trial of Vosoritide in Children with Hypochondroplasia

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider